David A. Siegel Immunovant, Inc. Transaction History

Two Sigma Advisers, LP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$31.31 - $44.19 $18.2 Million - $25.7 Million	-580,900 Reduced 96.77%	19,400 $817,000
Q3 2023 Nov 14, 2023	SELL	$18.55 - $39.96 $6.26 Million - $13.5 Million	-337,600 Reduced 36.0%	600,300 $23 Million
Q2 2023 Aug 14, 2023	BUY	$14.2 - $23.75 $1.39 Million - $2.32 Million	97,800 Added 11.64%	937,900 $17.8 Million
Q1 2023 May 15, 2023	BUY	$15.27 - $19.72 $7.01 Million - $9.06 Million	459,200 Added 120.56%	840,100 $13 Million
Q4 2022 Feb 14, 2023	BUY	$6.59 - $17.75 $260,964 - $702,900	39,600 Added 11.6%	380,900 $6.76 Million
Q3 2022 Nov 14, 2022	SELL	$3.93 - $6.37 $782,463 - $1.27 Million	-199,100 Reduced 36.84%	341,300 $1.9 Million
Q2 2022 Aug 15, 2022	SELL	$3.38 - $5.65 $576,628 - $963,890	-170,600 Reduced 23.99%	540,400 $2.11 Million
Q1 2022 May 16, 2022	SELL	$5.06 - $8.77 $107,777 - $186,801	-21,300 Reduced 2.91%	711,000 $3.92 Million
Q4 2021 Feb 14, 2022	SELL	$7.33 - $9.32 $2.02 Million - $2.57 Million	-276,200 Reduced 27.39%	732,300 $6.24 Million
Q3 2021 Nov 15, 2021	BUY	$7.01 - $11.37 $1.29 Million - $2.1 Million	184,500 Added 22.39%	1,008,500 $8.76 Million
Q2 2021 Aug 16, 2021	BUY	$9.4 - $16.85 $2.29 Million - $4.1 Million	243,500 Added 41.95%	824,000 $8.71 Million
Q1 2021 May 17, 2021	BUY	$13.08 - $49.6 $7.54 Million - $28.6 Million	576,100 Added 13093.18%	580,500 $9.31 Million
Q4 2020 Feb 16, 2021	BUY	$36.36 - $52.71 $159,984 - $231,924	4,400 New	4,400 $203,000

212

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.